Screener
Adaptive Biotechnologies ADPT Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $70,874 | $52,443 |
| Operating expenses | ||
| Cost of revenue | 18,708 | 16,979 |
| Research and development | 23,623 | 24,203 |
| Sales and marketing | 26,346 | 23,047 |
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's total revenue?
- Adaptive Biotechnologies (ADPT) reported total revenue of $70.87M in Q1 2026.
- How has Adaptive Biotechnologies's total revenue changed year-over-year?
- Adaptive Biotechnologies's total revenue increased by 35.1% year-over-year, from $52.44M to $70.87M.
- What is the long-term trend for Adaptive Biotechnologies's total revenue?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's total revenue has grown at a 15.7% compound annual growth rate (CAGR), from $154.34M to $276.98M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Adaptive Biotechnologies's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude